17054例非小细胞肺癌中ALK的表达及临床病理特征分析  

Analysis of ALK expression and clinicopathological characteristics in 17054 cases of non-small cell lung cancer

作　　者：陈红 尤志群 谢英红 郭霞 雷哲[1] 顾冬梅[1] CHEN Hong;YOU Zhiqun;XIE Yinghong;GUO Xia;LEI Zhe;GU Dongmei(Department of Pathology,the First Affiliated Hospital of Soochow University,Jiangsu Province,Suzhou 215006,China)

机构地区：[1]苏州大学附属第一医院病理科,江苏苏州215006

出　　处：《中国医药导报》2024年第36期122-126,共5页China Medical Herald

摘　　要：目的探讨非小细胞肺癌(NSCLC)中间变性淋巴瘤激酶(ALK)的表达及与患者临床病理特征的关系。方法采用免疫组织化学技术对苏州大学附属第一医院病理科2014年6月至2022年12月收集的17054例NSCLC标本进行ALK蛋白检测,统计并分析ALK蛋白的表达与临床病理特征的关系。结果17054例NSCLC标本中,ALK阳性病例447例,阳性率为2.62%(447/17054)。女性患者ALK阳性率为2.98%(275/9223),男性患者ALK阳性率为2.20%(172/7831),女性患者ALK阳性率高于男性(P<0.05);在年龄<50岁和≥50岁的NSCLC患者中,ALK阳性率分别为3.90%和2.26%,年龄<50岁的NSCLC患者ALK阳性率高于年龄≥50岁的NSCLC患者;在10710例肺浸润性腺癌患者中,381例发生ALK基因融合,ALK阳性率为3.56%。ALK基因融合在浸润性肺腺癌患者中的发生率高于病理类型为原位腺癌、微浸润性腺癌、鳞癌的患者,差异有统计学意义(P<0.05)。Ki-67表达水平在5%~50%多见,占ALK阳性病例总数的77.40%(346/447)。结论年龄(<50岁)、女性、病理类型为浸润性腺癌的患者是ALK基因融合的高发人群,临床医师对此类患者人群进行ALK基因检测,指导患者个体化治疗,可获得更大临床益处。Objective To investigate the expression of anaplastic lymphoma kinase(ALK)in non-small cell lung cancer(NSCLC)and its relationship with clinicopathologic features.Methods The chemical technology of immunohistochemicals was used to detect ALK protein from 17054 non-small cell lung cancer specimens collected from June 2014 to December 2022,which was collected from June 2014 to December 2022,and analyzed the relationship between ALK’s expression and clinical pathological characteristics.Results In 17054 cases of NSCLC specimens,447 ALK-positive cases were positive,and the positive rate was 2.62%(447/17054).The positive rate of ALK in female patients was 2.98%(275/9223),the positive rate of ALK in male patients was 2.20%(172/7831).Women were more prone to ALK gene fusion than men(P<0.05).For patients with NSCLC,positive rates of ALK were 3.90%and 2.26%,respectively.The positive rate of ALK in NSCLC patients with<50 years old was higher than NSCLC patients≥50 years old(P<0.05).Among 10710 patients with lung infiltrated adenocarcinoma,381 cases occur in ALK,ALK positives occur rate was 3.56%.The incidence of ALK genes fused in patients with infiltrated pulmonary adenocarcinoma was much higher than those with pathological types with in situ adenocarcinoma,micro-infiltrated adenocarcinoma,and squamous carcinoma,the differences were statistically significant(P<0.05).The Ki-67 expression level is more common at 5%-50%,accounting for 77.40%(346/447)for ALK-positive cases.Conclusion Patients with<50 years old,women,and pathological types are high-incidence of ALK gene fusion.Clinicians conduct ALK tests on such patients can guide patients with individualized treatment,and obtain greater clinical benefits.

关 键 词：非小细胞肺癌 间变性淋巴瘤激酶 临床病理特征 

分 类 号：R734.2[医药卫生—肿瘤]